# Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

> **NCT02745535** · PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 77 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir/Velpatasvir/Voxilaprevir

## Key facts

- **NCT ID:** NCT02745535
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-10-24
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745535, "Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02745535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*